Prevalent S&P 500 Pharmaceuticals Company

TechValidate Customer Research Library / Prevalent / Case Studies /

Prevalent Case Study

S&P 500 Pharmaceuticals Company

Introduction

This case study of a S&P 500 pharmaceuticals company is based on a June 2021 survey of Prevalent customers by TechValidate, a 3rd-party research service. The profiled company asked to have their name blinded to protect their confidentiality.

“It has enhanced it and reduced turnaround times immensly.”

Challenges

Their primary vendor risk assessment pain points were:
- Too much time spent manually onboarding new vendors
- Complex, manual assessment processes (e.g., using spreadsheets)

Use Case

Currently assessing their vendors for the following:
- Cybersecurity

Results

Level of agreement:
- Prevalent provides the inherent risk visibility they need to focus on specific areas of their vendors’ risks: strongly agree
- Prevalent provides the real-time cybersecurity, reputational and financial intelligence they need: agree
Prevalent is critical on the following vendor lifecycle stages:
- Intake and vendor onboarding: essential
  **Scoring inherent risks: very Important
- Assessing vendors and remediating risks: critical
Strongly agree with the following:
- Prevalent allows us to do our job more effectively
- Prevalent’s vendor risk assessment process is invaluable to our group
- Prevalent reduced the time and complexity required to perform vendor risk assessments
We have realized major cost savings with Prevalent’s vendor risk management process.: agree

TechValidate Research on Prevalent

S&P 500 Pharmaceuticals Company

Introduction

Challenges

Use Case

Results

Company Profile

About Prevalent

About This Data